Biotech News

AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability

AngioDynamics (ANGO)AngioDynamics2026-06-25 13:46 ESTFDA / regulatory

Med Tech segment delivers fifth consecutive quarter of double-digit growth Strong adjusted EBITDA; and positive cash flow Three regulatory milestones support Mechanical Thrombectomy portfolio: Modified AlphaVac 510(k) clearance, PAVE and APEX-Return IDE approvals Raised full year FY 2026 guidance

Open original release

Related news

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform

ANGOAngioDynamics2026-06-25 13:46 EST

AngioDynamics to Present at the Leerink Partners Global Healthcare Conference

View all latest news

AngioDynamics

AngioDynamics is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ANGOAngioDynamics2026-06-26 08:29 EST

AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)

ANGOAngioDynamics2026-06-26 08:29 EST

AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect

ANGOAngioDynamics2026-06-26 08:29 EST

AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

ANGOAngioDynamics2026-06-26 08:29 EST

AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer

ANGOAngioDynamics2026-06-26 08:29 EST

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States